Repare Therapeutics Long Term Debt 2020-2025 | RPTX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Repare Therapeutics long term debt from 2020 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Repare Therapeutics long term debt from 2020 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$218.6B
Amgen (AMGN)	$164.4B
Gilead Sciences (GILD)	$137B
Vertex Pharmaceuticals (VRTX)	$120.7B
Bristol Myers Squibb (BMY)	$97.7B
CSL (CSLLY)	$84.2B
GSK (GSK)	$75.8B
Regeneron Pharmaceuticals (REGN)	$60.6B
Alnylam Pharmaceuticals (ALNY)	$42.4B
Argenex SE (ARGX)	$35B
BioNTech SE (BNTX)	$26.8B
Royalty Pharma (RPRX)	$20.3B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18.7B
Illumina (ILMN)	$16.2B
Genmab (GMAB)	$14B
Genmab (GNMSF)	$13.8B
Incyte (INCY)	$13.3B
Moderna (MRNA)	$12.7B
Exelixis (EXEL)	$12.1B
BioMarin Pharmaceutical (BMRN)	$11.4B
QIAGEN (QGEN)	$11B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.1B
Exact Sciences (EXAS)	$9.4B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$8.3B
Legend Biotech (LEGN)	$8.1B
Roivant Sciences (ROIV)	$7.8B